WO1998029139A1 - PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b) - Google Patents

PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b) Download PDF

Info

Publication number
WO1998029139A1
WO1998029139A1 PCT/RU1996/000357 RU9600357W WO9829139A1 WO 1998029139 A1 WO1998029139 A1 WO 1998029139A1 RU 9600357 W RU9600357 W RU 9600357W WO 9829139 A1 WO9829139 A1 WO 9829139A1
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
radionuclide
labelled
organic compound
phosphorus
Prior art date
Application number
PCT/RU1996/000357
Other languages
English (en)
Russian (ru)
Inventor
Jury Samoilovich Skoblov
Anatoly Petrovich Losev
Eduard Yakovlevich Smetanin
Zhan Pier Frideling
Alexei Eduardovich Korolev
Nadina Gzhiva
Original Assignee
Gosudarstvenny Nauchny Tsentr Fiziko-Energetichesky Institut
Isotopchim S.A.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gosudarstvenny Nauchny Tsentr Fiziko-Energetichesky Institut, Isotopchim S.A.R.L. filed Critical Gosudarstvenny Nauchny Tsentr Fiziko-Energetichesky Institut
Priority to PCT/RU1996/000357 priority Critical patent/WO1998029139A1/fr
Publication of WO1998029139A1 publication Critical patent/WO1998029139A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers

Definitions

  • the invention relates to the areas of biological active compounds labeled with radionclides.
  • the components of such devices are forced to solve problems not only the synthesis of 0 targets in the connection, but in the case of problems.
  • aquatic biologically active substances add special substances - radioactive substances or stabilization.
  • the known use of the radioactive substances in the following substances is as follows: [1, amine [1], tar [3], S-acid, and 51 p-acid.
  • “Classical” materials and radiators for labeled Yel compounds add specific reagents. This makes the products labeled with compounds not only more convenient in operation, but also provides a visual control for 5 manipulations with radioactive devices. Its main disadvantage is the extremely convenient use of vehicles for “inexperience” of medical devices and biomedical devices.
  • 20 tha cars offer free shipping. containing an organic compound labeled with a radionuclide, for example, phosphorus-32, phosphor-33 or sulfur-35. Spare in water, and radioactive, as a rule, they use material of the class ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ISA ⁇ ..
  • D ⁇ bavlenie B ⁇ e ⁇ a ⁇ a ⁇ ⁇ i ⁇ in ⁇ v, HA ⁇ ⁇ ime ⁇ ⁇ i ⁇ a tsian ⁇ balamina, ⁇ bes ⁇ echivae ⁇ ⁇ dn ⁇ emenn ⁇ e ⁇ e ⁇ ⁇ adi ⁇ e ⁇ a and e ⁇ e ⁇ ⁇ ashivaniya ⁇ as ⁇ v ⁇ a, ⁇ a ⁇ ⁇ a ⁇ ⁇ i ⁇ iny ⁇ bychn ⁇ in ⁇ ensivn ⁇ ⁇ asheny.
  • the range of effective concentrations for cyanobalamin (Vitamin ⁇ 12) is 0.1 to 4.0 mg / ml. ⁇ note ⁇ , ⁇ ⁇ 98/29139 ⁇ / ⁇ 96 / 00357
  • Vitamin ⁇ 12 For the convenience of radioactivity, the use of Vitamin ⁇ 12.
  • fosf-32- the stability of the biologically active active substances is protected
  • a further increase in the amount of radionuclide in the sample makes the aqueous products even more unstable.
  • the biological activity of the radioactive product did not change during the entire 0 storage period.
  • Subsequent studies have shown that the addition of oximetilaminomethane ( ⁇ IS) to the indispensable compound increases the stability of 5 labeled compounds.
  • ⁇ IS oximetilaminomethane
  • EXAMPLE 1 To stabilize the product [y- 32 ⁇ ] ⁇ with a volume activity of 15 mI / ml in the amount of 0.05 ml ⁇ ⁇ 98/29139 ⁇ 7 ⁇ 96 / 00357
  • EXAMPLE 2 To stabilize ⁇ D ⁇ ⁇ device [ ⁇ - 3 ⁇ ] ⁇ with a volumetric activity of 15 MI / ml in the amount of 0.5 ml, we used the method of stabilizing the saline. Prevention 0 There was room for a large temperature (around 20 ° ⁇ ). The analysis was made, as it was in the previous one. The results are presented in table 2. ⁇ 96 / 00357
  • Table 2 shows values of a radically 5 percent in% and, after other things, an appropriate biological activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)

Abstract

Cette invention concerne la production de préparations contenant des composés biologiquement actifs qui sont marqués à l'aide d'un radionucléide β tel que du phosphore 32, du phosphore 33 ou du soufre 35. Ces préparations peuvent être utilisées dans la recherche biologique ou à des fins médicales. Cette invention concerne essentiellement une préparation contenant un composé organique qui est marqué à l'aide d'un radionucléide β et qui est soluble dans l'eau. Cette préparation contient également un radio-protecteur en qualité duquel on peut utiliser une substance appartenant à la classe des porphyrines ou une forme polymère de cette substance. Cette substance peut par exemple consister en du cyancobalamine, tandis que sa concentration optimale dans la préparation varie de 0,1 à 4,0 mg/ml. L'addition à cette préparation de 40 à 60 m.moles/l. de trioxyméthylaminométhane permet d'accroître la stabilité des composés marqués. Il est ainsi possible d'accroître le temps de conservation de ladite préparation, et d'augmenter sa température de stockage et de transport jusqu'à une plage de 0 à 25 °C. Cette invention permet en outre de faciliter le contrôle visuel lorsque l'on travaille avec des micro-quantités de préparation radioactive, ceci sans qu'il soit nécessaire d'ajouter un système colorant complémentaire.
PCT/RU1996/000357 1996-12-25 1996-12-25 PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b) WO1998029139A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/RU1996/000357 WO1998029139A1 (fr) 1996-12-25 1996-12-25 PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU1996/000357 WO1998029139A1 (fr) 1996-12-25 1996-12-25 PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b)

Publications (1)

Publication Number Publication Date
WO1998029139A1 true WO1998029139A1 (fr) 1998-07-09

Family

ID=20130064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1996/000357 WO1998029139A1 (fr) 1996-12-25 1996-12-25 PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b)

Country Status (1)

Country Link
WO (1) WO1998029139A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011021A1 (fr) 2005-07-22 2007-01-25 Meiji Seika Kaisha, Ltd. Procédé de production de dérivé d’imidazothiazole

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU683750A1 (ru) * 1974-07-29 1979-09-05 Институт биофизики Способ получени препарата инди 113 м дл скеннировани масс крови
EP0006658A1 (fr) * 1978-06-28 1980-01-09 THE PROCTER & GAMBLE COMPANY Agents de radiodiagnostic contenant hydroquinone comme stabilisant et leur procédé de préparation
WO1993015765A1 (fr) * 1992-02-14 1993-08-19 Mallinckrodt Medical, Inc. Kits radiopharmaceutiques stabilises
US5262175A (en) * 1989-05-10 1993-11-16 Solanki Kishor K Stabilization of radiopharmaceutical compositions
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU683750A1 (ru) * 1974-07-29 1979-09-05 Институт биофизики Способ получени препарата инди 113 м дл скеннировани масс крови
EP0006658A1 (fr) * 1978-06-28 1980-01-09 THE PROCTER & GAMBLE COMPANY Agents de radiodiagnostic contenant hydroquinone comme stabilisant et leur procédé de préparation
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5262175A (en) * 1989-05-10 1993-11-16 Solanki Kishor K Stabilization of radiopharmaceutical compositions
WO1993015765A1 (fr) * 1992-02-14 1993-08-19 Mallinckrodt Medical, Inc. Kits radiopharmaceutiques stabilises

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011021A1 (fr) 2005-07-22 2007-01-25 Meiji Seika Kaisha, Ltd. Procédé de production de dérivé d’imidazothiazole

Similar Documents

Publication Publication Date Title
AU656915B2 (en) Stabilized therapeutic radiopharmaceutical complexes
JPS63145239A (ja) Ｎｍｒ診断剤およびその製法
Enna et al. Phenol red absorption from the rat lung: evidence of carrier transport
Christel et al. Pharmacokinetics of cyanide in poisoning of dogs, and the effect of 4-dimethylaminophenol or thiosulfate
Wagner Appraisal of digoxin bioavailability and pharmacokinetics in relation to cardiac therapy
Burton et al. Absorption of sulphonamides and antitubercular drugs from the rat lung
Brooks et al. Labelling of inulin with radioactive iodine
DeMartino et al. Uncaging carbon disulfide. Delivery platforms for potential pharmacological applications: a mechanistic approach
WO1998029139A1 (fr) PREPARATION CONTENANT UN COMPOSE ORGANIQUE MARQUE A L'AIDE D'UN RADIONUCLEIDE $g(b)
US4431626A (en) Tc-99m Labeled carrier for imaging
JPS585887B2 (ja) ホウシヤセイイヤクヒン オヨビソノ セイゾウホウホウ
US3939258A (en) Process for the manufacture of human transferrin labelled with indium 113m
Ryo et al. Relative tissue distribution of radioactivity in rats with endocrine “autonomous” breast carcinomas after 3H-, 99mTc-, and 64Cu-bleomycin
Barlow et al. Preparation and characterization of tritiated heparin
CS240957B2 (en) Production method of stabile solution containing iron and selenium
US3743713A (en) Preparation of radioactive mono and di-iodosulfobromophthalein
Andrews et al. 676. A radioactive drug: 2-methyl-6-tritio-1, 4-naphthaquinol bis-(disodium phosphate) and 2-methyl-5, 6, 7-tritritio-1, 4-naphthaquinol bis (disodium phosphate)
Wilson Fluid movement across the wall of the small intestine in vitro
CN104926710A (zh) 卡络磺钠及其制法
Merchante et al. Conversion of porphobilinogen to porphyrin by liver homogenates of rats with experimental hepatic porphyria.
RU2045282C1 (ru) Способ приготовления реагента для радиофармпрепаратов, меченных технецием-99
WO1999008709A1 (fr) Medicament radioactif stable
Hogben et al. Excretion of phosphate by isolated frog kidney: an ‘adsorption semipermeability’model for maximal tubular transport
Ball Toxicity of dimethyl sulphoxide to the goldfish, Carassius auratus
RU2164420C2 (ru) Способ получения радиотерапевтического препарата

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA HU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase